The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).
Paul Joseph Hesketh
Consultant or Advisory Role - Helsinn Therapeutics
Honoraria - Helsinn Therapeutics
Giorgia Rossi
Employment or Leadership Position - Helsinn Therapeutics
Giada Rizzi
Employment or Leadership Position - Helsinn Therapeutics
Marco Palmas
Employment or Leadership Position - Helsinn Therapeutics
Anna Alyasova
No relevant relationships to disclose
Igor Drobner
No relevant relationships to disclose
Richard J. Gralla
Consultant or Advisory Role - Helsinn Therapeutics
Honoraria - Helsinn Therapeutics